(Q36859983)

16 August 2017

1 reference

title

Osteoporosis in men and women (English)

1 reference

16 August 2017

Sydney L Bonnick

1

1 reference

16 August 2017

language of work or name

1 reference

1 January 2006

1 reference

16 August 2017

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

28-39

1 reference

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

1 reference

7 January 2021

Male osteoporosis: new trends in diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Bone mineral density and mortality in elderly men and women: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Increasing sex difference in bone strength in old age: The Age, Gene/Environment Susceptibility-Reykjavik study (AGES-REYKJAVIK).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Assessment of fracture risk: who should be treated for osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

The incidence of vertebral fractures in men and women: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Risk factors for incident vertebral fractures in men and women: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Body composition changes with age have gender-specific impacts on bone mineral density.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Diagnosis of osteoporosis in men, premenopausal women, and children

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

RETRACTED: Risedronate therapy for prevention of hip fracture after stroke in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Bisphosphonates: preclinical review

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980063-3

7 January 2021

10.1016/S1098-3597(06)80063-3

Identifiers

DOI

1 reference

16 August 2017

1 reference